About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials | 7,992 Studies Recruiting

Clinical TrialsLung Cancer

Lung Cancer Clinical Trials

Browse 7,992 clinical trials for lung cancer. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 3361-3380 of 7,992 trials

TerminatedOpen-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.NCT02393248·Birmingham, Alabama and 19 others CompletedKey Performance Indicators for the Assessment of NSCLC Patients PathwayThis is a multicenter, observational study involving a retrospective collection of data.NCT04676321·Meldola, Forlì-Cesena and 2 others

Related Searches

nsclctrials sclctrials lung carcinomatrials

Data from ClinicalTrials.govTerms

UnknownEffect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer PatientsThe myeloid-derived suppressor cells (MDSCs) can further trigger cytotoxic T cell apoptosis, and may shift the macrophages toward M2 subtype, inhibit the Th1 cell, and initiate…NCT01802021·Gueishan Township, Taoyuan County

RecruitingSerplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%This prospective clinical study aims to evaluate and observe the efficacy and safety of Serplulimab Monotherapy in Elderly Patients with NSCLC and PD-L1 TPS ≥ 50% using a…NCT07596121·Xi'an, Shannxi

CompletedEribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung CancerThis is a Phase 2, multicenter, randomized study of two different dose regimens of eribulin mesylate in combination with intermittent erlotinib in patients with previously…NCT01104155·Bessemer, Alabama and 63 others

CompletedStudy to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain MetastasesA multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative…NCT05807893·Guangzhou, Guangdong

CompletedStudy of Intermittent OSI-906 DosingMulticenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.NCT00514306·Houston, Texas and 1 other

UnknownHeterogeneity of Dendritic Cells in Colon and Non-small Cell Lung CancerProspective study with the use of biological samples. The centers involved are the Thoracic Surgery and Surgery 1 Units of the San Gerardo Hospital in Monza.NCT04789252·Monza and 1 other

RecruitingA Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung CancerThis is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC.NCT07538804·Fairfax, Virginia and 4 others

TerminatedMP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLCThe purpose of this study is to assess the anti-tumor efficacy, safety, tolerability, pharmacokinetics (PK), immunogenicity and biological activity of the MP0250 DARPin® drug…NCT03418532·Scottsdale, Arizona and 9 others

UnknownPhase 1 Study of BPI-442096 in Advanced Solid Tumor PatientsA first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in…NCT05369312·Guangzhou, Guangdong and 4 others

UnknownSecond-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLCTo determine whether in docetaxel pretreated advanced NSCLC patients with favorable clinical parameter(s) gefitinib can produce different outcomes from patients without favorable…NCT00319800·Incheon

TerminatedA Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerThis trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas.NCT04254107·Birmingham, Alabama and 35 others

TerminatedDebio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid MalignanciesThis is a two-part trial in patients with squamous non-small cell lung cancer (NSCLC), platinum (Pt)-refractory ovarian cancer, and basal-like/claudin low triple negative breast…NCT01930292·Dijon and 3 others

TerminatedExhaled Breath Analysis to Predict Risk of Symptomatic PneumonitisThis is a prospective pilot study investigating exhaled breath condensate analyses to quantify the variability over time of various biomarkers associated with symptomatic…NCT04040244·Winston-Salem, North Carolina

UnknownElective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain MetastasesBrain metastases are the most common intracranial tumors in adults.NCT03414944·Jin'an, Shandong

Active not recruitingNivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.NCT02595944·Birmingham, Alabama and 883 others

CompletedPostoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional FractionationIn this randomized multicentric phase II study it will be investigated whether an accelerated postoperative radiotherapy with photons or protons (7 fractions per week, 2 Gy single…NCT02189967·Dresden and 8 others

UnknownA Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against…NCT04778800·Zhengzhou, Henan

TerminatedA Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung CancerAn Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or…NCT04432207·Phoenix, Arizona and 5 others

PreviousPage 169 of 400Next